P-614. Why Aren’t We Treating? Reasons for Antiviral Non-Prescription in Hospitalized Children with Influenza

Abstract Background Antiviral treatment is recommended for all children hospitalized with influenza to reduce disease severity and complications. However, antiviral use has declined since the COVID-19 pandemic. We aimed to investigate reasons for antiviral non-prescription in children hospitalized with influenza in Western NY.Table 1.Characteristics of Children Hospitalized with Influenza Stratified by Antiviral Treatment, 2023-2024Table 2.Themes and Associated Quotations: Reasons for Antiviral Non-Prescription Methods From 10/2023 to 4/2024, we identified children < 18 years of age hospitalized with a positive, laboratory-confirmed influenza test during or in the 14 days prior to hospitalization in a 7-county catchment area in Western, NY as part of CDC’s FluSurv-NET. Clinical and demographic data were abstracted from medical records and compared across treatment groups. Reasons for antiviral non-prescription were transcribed verbatim and analyzed qualitatively to identify key themes. Results 131 children were hospitalized with influenza during the surveillance period, of which 76 (58%) did not receive antiviral treatment. Untreated children had a shorter length of stay and were less likely to require ICU admission, non-invasive respiratory support or mechanical ventilation. They were also less likely to have a documented underlying condition. While most (96.2%) children presented with respiratory symptoms, untreated children were more likely to have gastrointestinal symptoms (Table 1). Reasons for antiviral non-prescription were documented for 50% of the untreated children; 4 themes emerged: 1) patient/family declination, 2) risk/benefit communication, 3) misunderstanding guidelines, and 4) medication intolerance. Providers frequently emphasized the risks of antivirals during family discussions and did not adhere to established treatment guidelines, withholding treatment in children with illness duration exceeding 2 days, or lacking high-risk conditions or respiratory symptoms (Table 2). Conclusion Over half of the children hospitalized with influenza did not receive antivirals, with treatment more common in children with greater medical complexity. Our findings highlight the need for further education to ensure treatment of all hospitalized children, regardless of duration of illness, comorbidities or symptomology. Additionally, there is a need for guidance on effective communication strategies to emphasize the benefits of antiviral treatment. Disclosures Brenda L. Tesini, MD, Merck: Honoraria

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.827
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-614. Why Aren’t We Treating? Reasons for Antiviral Non-Prescription in Hospitalized Children with Influenza

Maria A. Gaitan, Brenda L. Tesini, Erin Licherdell, Christina B Felsen
Open Forum Infectious Diseases
Respiratory viral infections research
article

P-614. Why Aren’t We Treating? Reasons for Antiviral Non-Prescription in Hospitalized Children with Influenza

Maria A. Gaitan, Brenda L. Tesini, Erin Licherdell, Christina B Felsen
article en

Abstract

Abstract Background Antiviral treatment is recommended for all children hospitalized with influenza to reduce disease severity and complications. However, antiviral use has declined since the COVID-19 pandemic. We aimed to investigate reasons for antiviral non-prescription in children hospitalized with influenza in Western NY.Table 1.Characteristics of Children Hospitalized with Influenza Stratified by Antiviral Treatment, 2023-2024Table 2.Themes and Associated Quotations: Reasons for Antiviral Non-Prescription Methods From 10/2023 to 4/2024, we identified children < 18 years of age hospitalized with a positive, laboratory-confirmed influenza test during or in the 14 days prior to hospitalization in a 7-county catchment area in Western, NY as part of CDC’s FluSurv-NET. Clinical and demographic data were abstracted from medical records and compared across treatment groups. Reasons for antiviral non-prescription were transcribed verbatim and analyzed qualitatively to identify key themes. Results 131 children were hospitalized with influenza during the surveillance period, of which 76 (58%) did not receive antiviral treatment. Untreated children had a shorter length of stay and were less likely to require ICU admission, non-invasive respiratory support or mechanical ventilation. They were also less likely to have a documented underlying condition. While most (96.2%) children presented with respiratory symptoms, untreated children were more likely to have gastrointestinal symptoms (Table 1). Reasons for antiviral non-prescription were documented for 50% of the untreated children; 4 themes emerged: 1) patient/family declination, 2) risk/benefit communication, 3) misunderstanding guidelines, and 4) medication intolerance. Providers frequently emphasized the risks of antivirals during family discussions and did not adhere to established treatment guidelines, withholding treatment in children with illness duration exceeding 2 days, or lacking high-risk conditions or respiratory symptoms (Table 2). Conclusion Over half of the children hospitalized with influenza did not receive antivirals, with treatment more common in children with greater medical complexity. Our findings highlight the need for further education to ensure treatment of all hospitalized children, regardless of duration of illness, comorbidities or symptomology. Additionally, there is a need for guidance on effective communication strategies to emphasize the benefits of antiviral treatment. Disclosures Brenda L. Tesini, MD, Merck: Honoraria

Open Forum Infectious DiseasesVol. 13(Supplement_1)
University of Rochester Medical Center (US), University of Rochester (US)
Good health and well-being
Openalex Percentile: Top 92%
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.